2018
DOI: 10.1111/imj.14053
|View full text |Cite
|
Sign up to set email alerts
|

Author reply

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2018
2018
2018
2018

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 9 publications
(12 reference statements)
0
2
0
Order By: Relevance
“…1 The citation for the advice provided does not make any reference to leflunomide. 7 Low-to-moderate doses of CS (dose equivalent to prednisone ≤10 mg/day), leflunomide, sulfasalazine and MTX (≤0.4 mg/kg per week) and AZA (≤3 mg/kg per day) are not a contraindication. 7 This error has the potential to result in a serious adverse event and needs urgent correction.…”
Section: No Live Vaccines For People Being Treated With Leflunomidementioning
confidence: 99%
See 1 more Smart Citation
“…1 The citation for the advice provided does not make any reference to leflunomide. 7 Low-to-moderate doses of CS (dose equivalent to prednisone ≤10 mg/day), leflunomide, sulfasalazine and MTX (≤0.4 mg/kg per week) and AZA (≤3 mg/kg per day) are not a contraindication. 7 This error has the potential to result in a serious adverse event and needs urgent correction.…”
Section: No Live Vaccines For People Being Treated With Leflunomidementioning
confidence: 99%
“…While disseminated HZ post-ZVL can occur, it is most often described in those with haematologic malignancy. 6,7 A US study of 14 554 people who had an…”
Section: Author Replymentioning
confidence: 99%